{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:57:48Z","timestamp":1761541068532},"reference-count":118,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.soc.2011.09.007","type":"journal-article","created":{"date-parts":[[2011,11,22]],"date-time":"2011-11-22T12:09:09Z","timestamp":1321963749000},"page":"161-175","source":"Crossref","is-referenced-by-count":5,"title":["Molecular Markers for Incidence, Prognosis, and Response to Therapy"],"prefix":"10.1016","volume":"21","author":[{"given":"Betty C.","family":"Tong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"David H.","family":"Harpole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.soc.2011.09.007_bib1","series-title":"Cancer facts & figures","author":"American Cancer Society","year":"2011"},{"issue":"9","key":"10.1016\/j.soc.2011.09.007_bib2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(01)00486-7","article-title":"Global cancer statistics in the year 2000","volume":"2","author":"Parkin","year":"2001","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.soc.2011.09.007_bib3","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","article-title":"The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J\u00a0Thorac Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.soc.2011.09.007_bib4","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1038\/onc.2009.200","article-title":"Individualized therapy in non-small-cell lung cancer: future versus current clinical practice","volume":"28","author":"Perez-Soler","year":"2009","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.soc.2011.09.007_bib5","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ejca.2008.03.006","article-title":"Prognostic versus predictive value of biomarkers in oncology","volume":"44","author":"Oldenhuis","year":"2008","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.soc.2011.09.007_bib6","first-page":"3155","article-title":"Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer","volume":"60","author":"Ahrendt","year":"2000","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"10.1016\/j.soc.2011.09.007_bib7","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/j.lungcan.2004.07.978","article-title":"Validation of molecular and immunological factors with predictive importance in lung cancer","volume":"45","author":"Fischer","year":"2004","journal-title":"Lung Cancer"},{"issue":"6810","key":"10.1016\/j.soc.2011.09.007_bib8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.soc.2011.09.007_bib9","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/jnci\/95.13.961","article-title":"p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study","volume":"95","author":"Ahrendt","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.soc.2011.09.007_bib10","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/bjc.1997.194","article-title":"K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer","volume":"75","author":"Fukuyama","year":"1997","journal-title":"Br J Cancer"},{"issue":"21","key":"10.1016\/j.soc.2011.09.007_bib11","first-page":"5572","article-title":"p53 null mutations undetected by\u00a0immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas","volume":"59","author":"Hashimoto","year":"1999","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib12","first-page":"1","article-title":"Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer","volume":"53","author":"Horio","year":"1993","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.soc.2011.09.007_bib13","first-page":"553","article-title":"Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer","volume":"12","author":"Huang","year":"1998","journal-title":"Int J Oncol"},{"issue":"4","key":"10.1016\/j.soc.2011.09.007_bib14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1183\/09031936.01.17406600","article-title":"Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer","volume":"17","author":"Laudanski","year":"2001","journal-title":"Eur Respir J"},{"issue":"24","key":"10.1016\/j.soc.2011.09.007_bib15","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1093\/jnci\/85.24.2018","article-title":"Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer","volume":"85","author":"Mitsudomi","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.soc.2011.09.007_bib16","first-page":"1031","article-title":"p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients","volume":"6","author":"Skaug","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.soc.2011.09.007_bib17","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/sj.onc.1202384","article-title":"Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma","volume":"18","author":"Tomizawa","year":"1999","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/bjc.1997.334","article-title":"p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer","volume":"76","author":"Vega","year":"1997","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/(SICI)1096-9896(199601)178:1<53::AID-PATH415>3.0.CO;2-T","article-title":"Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma","volume":"178","author":"Dalquen","year":"1996","journal-title":"J\u00a0Pathol"},{"issue":"4","key":"10.1016\/j.soc.2011.09.007_bib20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0022-5223(99)70294-1","article-title":"A\u00a0biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers","volume":"117","author":"D\u2019Amico","year":"1999","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib21","first-page":"51","article-title":"A\u00a0prognostic model of\u00a0recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression","volume":"55","author":"Harpole","year":"1995","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.soc.2011.09.007_bib22","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1200\/JCO.1998.16.7.2468","article-title":"Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications","volume":"16","author":"Kwiatkowski","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2011.09.007_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0003-4975(99)00618-9","article-title":"Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers","volume":"68","author":"Lee","year":"1999","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.soc.2011.09.007_bib24","first-page":"1125","article-title":"Predictive survival markers in patients with surgically resected non-small cell lung carcinoma","volume":"6","author":"Moldvay","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.soc.2011.09.007_bib25","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1200\/JCO.1996.14.2.497","article-title":"Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers","volume":"14","author":"Nishio","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib26","first-page":"155","article-title":"p53 protein in non-small cell lung cancer as quantitated by enzyme-linked immunosorbent assay: relation to prognosis","volume":"2","author":"Pappot","year":"1996","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.soc.2011.09.007_bib27","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1200\/JCO.1997.15.8.2858","article-title":"Immunocytochemical markers in\u00a0stage I lung cancer: relevance to prognosis","volume":"15","author":"Pastorino","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2011.09.007_bib28","first-page":"545","article-title":"Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery","volume":"43","author":"Carbognani","year":"2002","journal-title":"J\u00a0Cardiovasc Surg (Torino)"},{"issue":"33","key":"10.1016\/j.soc.2011.09.007_bib29","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1200\/JCO.2007.12.6953","article-title":"Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer","volume":"25","author":"Tsao","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2011.09.007_bib30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1183\/09031936.01.00062201","article-title":"Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis","volume":"18","author":"Steels","year":"2001","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.soc.2011.09.007_bib31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000085376","article-title":"Molecular pathology of non-small-cell lung cancer","volume":"72","author":"Breuer","year":"2005","journal-title":"Respiration"},{"issue":"6","key":"10.1016\/j.soc.2011.09.007_bib32","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H","article-title":"Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung","volume":"92","author":"Ahrendt","year":"2001","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.soc.2011.09.007_bib33","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.4161\/cc.9.20.13588","article-title":"Novel insights into the molecular origins and treatment of lung cancer","volume":"9","author":"Webb","year":"2010","journal-title":"Cell Cycle"},{"issue":"18","key":"10.1016\/j.soc.2011.09.007_bib34","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1158\/1078-0432.CCR-08-0646","article-title":"Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma","volume":"14","author":"Riely","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.soc.2011.09.007_bib35","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/jnci\/91.23.2032","article-title":"Implications and prognostic value of K-ras mutation for early-stage lung cancer in women","volume":"91","author":"Nelson","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"25","key":"10.1016\/j.soc.2011.09.007_bib36","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1200\/JCO.2005.02.857","article-title":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","volume":"23","author":"Eberhard","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib37","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1371\/journal.pmed.0020017","article-title":"KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.soc.2011.09.007_bib38","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/carcin\/20.8.1507","article-title":"K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases","volume":"20","author":"Huncharek","year":"1999","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.soc.2011.09.007_bib39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.critrevonc.2004.10.007","article-title":"Molecular prognostic factors in resectable non-small cell lung cancer","volume":"53","author":"Vielh","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.soc.2011.09.007_bib40","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1378\/chest.127.3.978","article-title":"ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer","volume":"127","author":"Simon","year":"2005","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.soc.2011.09.007_bib41","first-page":"144","article-title":"Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers","volume":"15","author":"Ikeda","year":"2009","journal-title":"Ann Thorac Cardiovasc Surg"},{"issue":"7","key":"10.1016\/j.soc.2011.09.007_bib42","first-page":"2286","article-title":"Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer","volume":"8","author":"Lord","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.soc.2011.09.007_bib43","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.soc.2011.09.007_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0169-5002(02)00301-X","article-title":"Clinical significance of P16INK4A and retinoblastoma proteins in non-small-cell lung carcinoma","volume":"38","author":"Akin","year":"2002","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.soc.2011.09.007_bib45","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0003-4975(03)00119-X","article-title":"Ki-67 expression and prognosis for smokers with resected stage I non-small cell lung cancer","volume":"75","author":"Haga","year":"2003","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"10.1016\/j.soc.2011.09.007_bib46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0169-5002(01)00225-2","article-title":"Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II","volume":"34","author":"Jin","year":"2001","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib47","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1158\/1078-0432.232.11.1","article-title":"Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma","volume":"11","author":"Burke","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.soc.2011.09.007_bib48","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1002\/cncr.22651","article-title":"Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer","volume":"109","author":"Mohamed","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.soc.2011.09.007_bib49","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0022-5223(99)70192-3","article-title":"Independent prognostic role of p16 expression in lung cancer","volume":"118","author":"Groeger","year":"1999","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"issue":"2","key":"10.1016\/j.soc.2011.09.007_bib50","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1054\/bjoc.1999.0929","article-title":"p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung","volume":"82","author":"Huang","year":"2000","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/(SICI)1097-0215(19990219)84:1<49::AID-IJC10>3.0.CO;2-Y","article-title":"p16 inactivation in small-sized lung adenocarcinoma: its association with poor prognosis","volume":"84","author":"Kawabuchi","year":"1999","journal-title":"Int J Cancer"},{"issue":"15","key":"10.1016\/j.soc.2011.09.007_bib52","first-page":"3415","article-title":"Rb and p16INK4a expression in resected non-small cell lung tumors","volume":"56","author":"Kratzke","year":"1996","journal-title":"Cancer Res"},{"issue":"2\u20133","key":"10.1016\/j.soc.2011.09.007_bib53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0169-5002(01)00196-9","article-title":"Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours","volume":"33","author":"Gugger","year":"2001","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.soc.2011.09.007_bib54","first-page":"1051","article-title":"Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers","volume":"3","author":"Nishio","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.bjc.6690661","article-title":"Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer","volume":"81","author":"Keum","year":"1999","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.soc.2011.09.007_bib56","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/JTO.0b013e3181e77efc","article-title":"Deregulation of p27 and cyclin D1\/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients","volume":"5","author":"Sterlacci","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.soc.2011.09.007_bib57","first-page":"242","article-title":"Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer","volume":"60","author":"Fukuse","year":"2000","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib58","first-page":"11","article-title":"Cyclin E expression, a potential prognostic marker for non-small cell lung cancers","volume":"6","author":"Mishina","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.soc.2011.09.007_bib59","first-page":"351","article-title":"Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers","volume":"62","author":"Soria","year":"2002","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.soc.2011.09.007_bib60","first-page":"3381","article-title":"Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer","volume":"57","author":"Esposito","year":"1997","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.soc.2011.09.007_bib61","first-page":"1831","article-title":"p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung","volume":"3","author":"Komiya","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.soc.2011.09.007_bib62","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1200\/JCO.2002.09.147","article-title":"Clinical significance of p21 expression in non-small-celllung cancer","volume":"20","author":"Shoji","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.soc.2011.09.007_bib63","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1158\/1078-0432.CCR-10-2316","article-title":"Reduced p21(WAF1\/CIP1) via alteration of p53-DDX3 pathway is associated with poor relapse-free survival in early-stage human papillomavirus-associated lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib64","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0169-5002(01)00211-2","article-title":"High cyclin E and low p27\/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients","volume":"34","author":"Hayashi","year":"2001","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.soc.2011.09.007_bib65","first-page":"4073","article-title":"Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers","volume":"6","author":"Hommura","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib66","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0169-5002(01)00216-1","article-title":"Reduced expression of cell-cycle regulator p27(Kip1) correlates with a shortened survival in non-small cell lung cancer","volume":"34","author":"Tsukamoto","year":"2001","journal-title":"Lung Cancer"},{"issue":"24","key":"10.1016\/j.soc.2011.09.007_bib67","doi-asserted-by":"crossref","first-page":"13790","DOI":"10.1073\/pnas.191502998","article-title":"Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses","volume":"98","author":"Bhattacharjee","year":"2001","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"2","key":"10.1016\/j.soc.2011.09.007_bib68","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1513\/pats.200807-076LC","article-title":"Genomics of lung cancer","volume":"6","author":"Borczuk","year":"2009","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.soc.2011.09.007_bib69","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1756-9966-27-38","article-title":"Identification of genes down-regulated during lung cancer progression: a cDNA array study","volume":"27","author":"Campioni","year":"2008","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"31","key":"10.1016\/j.soc.2011.09.007_bib70","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1200\/JCO.2005.05.1748","article-title":"Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts","volume":"24","author":"Hayes","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.soc.2011.09.007_bib71","first-page":"6116","article-title":"The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium","volume":"60","author":"Lerman","year":"2000","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.soc.2011.09.007_bib72","first-page":"3244","article-title":"Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles","volume":"62","author":"Miura","year":"2002","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.soc.2011.09.007_bib73","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/sj.onc.1206288","article-title":"Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs","volume":"22","author":"Kikuchi","year":"2003","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.soc.2011.09.007_bib74","first-page":"3005","article-title":"Molecular profiling of non-small cell lung cancer and correlation with disease-free survival","volume":"62","author":"Wigle","year":"2002","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.soc.2011.09.007_bib75","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nm733","article-title":"Gene-expression profiles predict survival of patients with lung adenocarcinoma","volume":"8","author":"Beer","year":"2002","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.soc.2011.09.007_bib76","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1172\/JCI32007","article-title":"Survival prediction of stage I lung adenocarcinomas by expression of 10 genes","volume":"117","author":"Bianchi","year":"2007","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa060096","article-title":"A\u00a0five-gene signature and clinical outcome in non-small-cell lung cancer","volume":"356","author":"Chen","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"35","key":"10.1016\/j.soc.2011.09.007_bib78","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1200\/JCO.2007.12.0352","article-title":"Three-gene prognostic classifier for early-stage non small-cell lung cancer","volume":"25","author":"Lau","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"12 Pt 2","key":"10.1016\/j.soc.2011.09.007_bib79","doi-asserted-by":"crossref","first-page":"4227s","DOI":"10.1158\/1078-0432.CCR-040007","article-title":"The biology of epidermal growth factor receptor in lung cancer","volume":"10","author":"Scagliotti","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.soc.2011.09.007_bib80","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1158\/0008-5472.CAN-05-1257","article-title":"Epidermal growth factor receptor mutations in patients with non-small cell lung cancer","volume":"65","author":"Johnson","year":"2005","journal-title":"Cancer Res"},{"issue":"9496","key":"10.1016\/j.soc.2011.09.007_bib81","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.soc.2011.09.007_bib82","first-page":"795","article-title":"Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer","volume":"26","author":"Masago","year":"2011","journal-title":"Oncol Rep"},{"issue":"10","key":"10.1016\/j.soc.2011.09.007_bib83","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.soc.2011.09.007_bib84","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1158\/1078-0432.CCR-05-0790","article-title":"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen","volume":"11","author":"Johnson","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1\u20132","key":"10.1016\/j.soc.2011.09.007_bib85","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1582-4934.2009.00991.x","article-title":"Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis","volume":"14","author":"Paz-Ares","year":"2010","journal-title":"J\u00a0Cell Mol Med"},{"issue":"11","key":"10.1016\/j.soc.2011.09.007_bib86","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.soc.2011.09.007_bib87","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/annonc\/mdm474","article-title":"Randomized phase II study of cetuximab plus cisplatin\/vinorelbine compared with cisplatin\/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer","volume":"19","author":"Rosell","year":"2008","journal-title":"Ann Oncol"},{"issue":"9674","key":"10.1016\/j.soc.2011.09.007_bib88","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.soc.2011.09.007_bib89","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.soc.2011.09.007_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.26381","article-title":"Bevacizumab and daily temozolomide for recurrent glioblastoma","author":"Desjardins","year":"2011","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.soc.2011.09.007_bib91","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.2011-S2-14","article-title":"Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence","volume":"16","author":"Hutson","year":"2011","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.soc.2011.09.007_bib92","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1535-7163.MCT-10-0239","article-title":"Targeted therapies for non-small cell lung cancer: an evolving landscape","volume":"9","author":"Pal","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"10.1016\/j.soc.2011.09.007_bib93","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-04-2661","article-title":"Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review","volume":"11","author":"Singhal","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.soc.2011.09.007_bib94","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.soc.2011.09.007_bib95","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann Oncol: official journal of the European Society for Medical Oncology\/ESMO"},{"issue":"7153","key":"10.1016\/j.soc.2011.09.007_bib96","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.soc.2011.09.007_bib97","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","article-title":"The biology and treatment of EML4-ALK non-small cell lung cancer","volume":"46","author":"Sasaki","year":"2010","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1016\/j.soc.2011.09.007_bib98","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.soc.2011.09.007_bib99","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.soc.2011.09.007_bib100","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/modpathol.2009.2","article-title":"EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset","volume":"22","author":"Inamura","year":"2009","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.soc.2011.09.007_bib101","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2353\/ajpath.2009.080755","article-title":"EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues","volume":"174","author":"Martelli","year":"2009","journal-title":"Am J Pathol"},{"issue":"12","key":"10.1016\/j.soc.2011.09.007_bib102","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1097\/JTO.0b013e318200f9ff","article-title":"Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer","volume":"5","author":"Ou","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10","key":"10.1016\/j.soc.2011.09.007_bib103","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jprot.2010.05.015","article-title":"Lung cancer proteomics, clinical and technological considerations","volume":"73","author":"Lehtio","year":"2010","journal-title":"J\u00a0Proteomics"},{"issue":"3","key":"10.1016\/j.soc.2011.09.007_bib104","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/sj.bjc.6604197","article-title":"Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy","volume":"98","author":"Maeda","year":"2008","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.soc.2011.09.007_bib105","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/JTO.0b013e31817e464a","article-title":"Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes","volume":"3","author":"Jacot","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"issue":"11","key":"10.1016\/j.soc.2011.09.007_bib106","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/jnci\/djk195","article-title":"Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study","volume":"99","author":"Taguchi","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.soc.2011.09.007_bib107","first-page":"1","article-title":"Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database","volume":"1","author":"Surati","year":"2011","journal-title":"J\u00a0Clin Bioinforma"},{"issue":"5","key":"10.1016\/j.soc.2011.09.007_bib108","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.soc.2011.09.007_bib109","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"10.1016\/j.soc.2011.09.007_bib110","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1056\/NEJMcibr051201","article-title":"MicroRNA and lung cancer","volume":"352","author":"Eder","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.soc.2011.09.007_bib111","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2005.01.014","article-title":"RAS is regulated by the let-7 microRNA family","volume":"120","author":"Johnson","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.soc.2011.09.007_bib112","doi-asserted-by":"crossref","DOI":"10.1515\/CCLM.2011.661","article-title":"Review: prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer","author":"Markou","year":"2011","journal-title":"Clin Chem Lab Med"},{"issue":"11","key":"10.1016\/j.soc.2011.09.007_bib113","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/0008-5472.CAN-04-0637","article-title":"Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival","volume":"64","author":"Takamizawa","year":"2004","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.soc.2011.09.007_bib114","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ccr.2006.01.025","article-title":"Unique microRNA molecular profiles in lung cancer diagnosis and prognosis","volume":"9","author":"Yanaihara","year":"2006","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.soc.2011.09.007_bib115","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/carcin\/bgp219","article-title":"miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer","volume":"30","author":"Gallardo","year":"2009","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.soc.2011.09.007_bib116","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2007.12.008","article-title":"MicroRNA signature predicts survival and relapse in lung cancer","volume":"13","author":"Yu","year":"2008","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.soc.2011.09.007_bib117","doi-asserted-by":"crossref","first-page":"8288","DOI":"10.1158\/0008-5472.CAN-10-1348","article-title":"MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma","volume":"70","author":"Voortman","year":"2010","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.soc.2011.09.007_bib118","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0186","article-title":"Adjuvant therapy in non-small cell lung cancer: current and future directions","volume":"15","author":"Sangha","year":"2010","journal-title":"Oncologist"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105532071100069X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105532071100069X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T07:46:44Z","timestamp":1686469604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105532071100069X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S105532071100069X"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2011.09.007","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}